Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ES414 · APVO-414

Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (PSMA) (FOLH1) and CD3 · developed by Aptevo Therapeutics

Phase 1 Most advanced trial (none active)

APVO Developer

1 Registered trials

What is ES414?

ES414 is a humanized bispecific antibody that binds prostate-specific membrane antigen (PSMA) on prostate cancer cells and redirects T-cell cytotoxicity against them. It is being studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: APVO-414
Drug type: Bispecific antibody
Targets: prostate-specific membrane antigen (PSMA) (FOLH1), CD3
Mechanism: Immune activation, directed at prostate-specific membrane antigen (PSMA) (FOLH1) and CD3
Pathways: T-cell cytotoxicity
Therapy area: Oncology
Developer: Aptevo Therapeutics (APVO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 56JX9SY1PG

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02262910	Phase 1	Prostate Cancer	Completed	APVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer

Other drugs acting on FOLH1

Gallium Ga 68 Gozetotide FDA approved Lutetium Lu 177 Rosopatamab Tetraxetan Phase 2

More from Aptevo Therapeutics

ALG.APV-527 Phase 1/2 APVO210 Phase 1 Mipletamig Phase 1 Otlertuzumab Phase 1/2

Sources

ClinicalTrials.gov NCT02262910

Updated Oct 11, 2026. Something wrong or missing? Report it on the APVO page.

Follow APVO, the company behind ES414

See APVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APVO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z